Awakn Life Sciences Provides a Business and Corporate Update
Phase III Trial to Cost approximately CA$3.75 million with Awakn's contribution expected to be approximately CA$1.25 million, Marks First Psychedelic ...
Phase III Trial to Cost approximately CA$3.75 million with Awakn's contribution expected to be approximately CA$1.25 million, Marks First Psychedelic ...
The Company is scheduled to begin production and analytical testing of MDMA this October in its recently completed EU-GMP pharmaceutical ...
A shroom boom is in the works, led by encouraging results from psychedelic medicine treatments for various issues associated with ...
A shroom boom is in the works, led by encouraging results from psychedelic medicine treatments for various issues associated with ...
Advertise your site, company or product to millions of web3, NFT and cryptocurrency enthusiasts. Learn more
© 2022 Altszn.com. All Rights Reserved.